234 related articles for article (PubMed ID: 19107227)
1. RET/PTC1-driven neoplastic transformation and proinvasive phenotype of human thyrocytes involve Met induction and beta-catenin nuclear translocation.
Cassinelli G; Favini E; Degl'Innocenti D; Salvi A; De Petro G; Pierotti MA; Zunino F; Borrello MG; Lanzi C
Neoplasia; 2009 Jan; 11(1):10-21. PubMed ID: 19107227
[TBL] [Abstract][Full Text] [Related]
2. Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene.
Borrello MG; Alberti L; Fischer A; Degl'innocenti D; Ferrario C; Gariboldi M; Marchesi F; Allavena P; Greco A; Collini P; Pilotti S; Cassinelli G; Bressan P; Fugazzola L; Mantovani A; Pierotti MA
Proc Natl Acad Sci U S A; 2005 Oct; 102(41):14825-30. PubMed ID: 16203990
[TBL] [Abstract][Full Text] [Related]
3. The beta-catenin axis integrates multiple signals downstream from RET/papillary thyroid carcinoma leading to cell proliferation.
Castellone MD; De Falco V; Rao DM; Bellelli R; Muthu M; Basolo F; Fusco A; Gutkind JS; Santoro M
Cancer Res; 2009 Mar; 69(5):1867-76. PubMed ID: 19223551
[TBL] [Abstract][Full Text] [Related]
4. RET/PTC1 oncogene signaling in PC Cl 3 thyroid cells requires the small GTP-binding protein Rho.
Barone MV; Sepe L; Melillo RM; Mineo A; Santelli G; Monaco C; Castellone MD; Tramontano D; Fusco A; Santoro M
Oncogene; 2001 Oct; 20(48):6973-82. PubMed ID: 11704822
[TBL] [Abstract][Full Text] [Related]
5. Concurrent overexpression of RET/PTC1 and TTF1 confers tumorigenicity to thyrocytes.
Endo T; Kobayashi T
Endocr Relat Cancer; 2013 Dec; 20(6):767-76. PubMed ID: 24014739
[TBL] [Abstract][Full Text] [Related]
6. Transcript level modulates the inherent oncogenicity of RET/PTC oncoproteins.
Richardson DS; Gujral TS; Peng S; Asa SL; Mulligan LM
Cancer Res; 2009 Jun; 69(11):4861-9. PubMed ID: 19487296
[TBL] [Abstract][Full Text] [Related]
7. Creation and characterization of a doxycycline-inducible mouse model of thyroid-targeted RET/PTC1 oncogene and luciferase reporter gene coexpression.
Knostman KA; Venkateswaran A; Zimmerman B; Capen CC; Jhiang SM
Thyroid; 2007 Dec; 17(12):1181-8. PubMed ID: 18004977
[TBL] [Abstract][Full Text] [Related]
8. Effects of silencing RET/PTC1 junction oncogene in human papillary thyroid carcinoma cells.
Gilbert-Sirieix M; Ripoche H; Malvy C; Massaad-Massade L
Thyroid; 2010 Oct; 20(10):1053-65. PubMed ID: 20615140
[TBL] [Abstract][Full Text] [Related]
9. A novel RET kinase-beta-catenin signaling pathway contributes to tumorigenesis in thyroid carcinoma.
Gujral TS; van Veelen W; Richardson DS; Myers SM; Meens JA; Acton DS; Duñach M; Elliott BE; Höppener JW; Mulligan LM
Cancer Res; 2008 Mar; 68(5):1338-46. PubMed ID: 18316596
[TBL] [Abstract][Full Text] [Related]
10. Early cellular abnormalities induced by RET/PTC1 oncogene in thyroid-targeted transgenic mice.
Cho JY; Sagartz JE; Capen CC; Mazzaferri EL; Jhiang SM
Oncogene; 1999 Jun; 18(24):3659-65. PubMed ID: 10380889
[TBL] [Abstract][Full Text] [Related]
11. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
[TBL] [Abstract][Full Text] [Related]
12. Thyroid carcinomas in RET/PTC transgenic mice.
Jhiang SM; Cho JY; Furminger TL; Sagartz JE; Tong Q; Capen CC; Mazzaferri EL
Recent Results Cancer Res; 1998; 154():265-70. PubMed ID: 10027006
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of Ret/Ptc1 oncoprotein and inhibition of papillary thyroid carcinoma cell proliferation by indolinone RPI-1.
Lanzi C; Cassinelli G; Cuccuru G; Zaffaroni N; Supino R; Vignati S; Zanchi C; Yamamoto M; Zunino F
Cell Mol Life Sci; 2003 Jul; 60(7):1449-59. PubMed ID: 12943231
[TBL] [Abstract][Full Text] [Related]
14. Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes.
Castellone MD; Cirafici AM; De Vita G; De Falco V; Malorni L; Tallini G; Fagin JA; Fusco A; Melillo RM; Santoro M
Oncogene; 2003 Jan; 22(2):246-55. PubMed ID: 12527893
[TBL] [Abstract][Full Text] [Related]
15. RET/papillary thyroid carcinoma oncogenic signaling through the Rap1 small GTPase.
De Falco V; Castellone MD; De Vita G; Cirafici AM; Hershman JM; Guerrero C; Fusco A; Melillo RM; Santoro M
Cancer Res; 2007 Jan; 67(1):381-90. PubMed ID: 17210721
[TBL] [Abstract][Full Text] [Related]
16. Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells.
Castellone MD; Celetti A; Guarino V; Cirafici AM; Basolo F; Giannini R; Medico E; Kruhoffer M; Orntoft TF; Curcio F; Fusco A; Melillo RM; Santoro M
Oncogene; 2004 Mar; 23(12):2188-96. PubMed ID: 14981541
[TBL] [Abstract][Full Text] [Related]
17. RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1.
Kim DW; Hwang JH; Suh JM; Kim H; Song JH; Hwang ES; Hwang IY; Park KC; Chung HK; Kim JM; Park J; Hemmings BA; Shong M
Mol Endocrinol; 2003 Jul; 17(7):1382-94. PubMed ID: 12738763
[TBL] [Abstract][Full Text] [Related]
18. Expression of the RET/PTC1 oncogene impairs the activity of TTF-1 and Pax-8 thyroid transcription factors.
De Vita G; Zannini M; Cirafici AM; Melillo RM; Di Lauro R; Fusco A; Santoro M
Cell Growth Differ; 1998 Jan; 9(1):97-103. PubMed ID: 9438393
[TBL] [Abstract][Full Text] [Related]
19. Papillary thyroid carcinoma: 6 cases from 2 families with associated lymphocytic thyroiditis harbouring RET/PTC rearrangements.
Mechler C; Bounacer A; Suarez H; Saint Frison M; Magois C; Aillet G; Gaulier A
Br J Cancer; 2001 Dec; 85(12):1831-7. PubMed ID: 11747322
[TBL] [Abstract][Full Text] [Related]
20. Conditional expression of RET/PTC induces a weak oncogenic drive in thyroid PCCL3 cells and inhibits thyrotropin action at multiple levels.
Wang J; Knauf JA; Basu S; Puxeddu E; Kuroda H; Santoro M; Fusco A; Fagin JA
Mol Endocrinol; 2003 Jul; 17(7):1425-36. PubMed ID: 12690093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
